Preferred Label : Anti-HER3 Antibody-drug Conjugate YL202;
NCIt synonyms : HER3-targeting Antibody-drug Conjugate YL202; Anti-HER3 ADC YL202;
NCIt definition : An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against
human epidermal growth factor receptor 3 (HER3; ErbB3) conjugated via a tumor microenvironment
(TME) activable protease-cleavable linker to a cytotoxic DNA topoisomerase I inhibitor,
with potential antineoplastic activity. Upon administration of anti-HER3 ADC YL202,
the anti-HER3 antibody moiety targets and binds to HER3 expressed on tumor cells.
Upon proteolytic cleavage in the TME and the release of the topoisomerase I inhibitor,
the topoisomerase I inhibitor targets and binds to DNA topoisomerase I, thereby stabilizing
the cleavable complex between topoisomerase I and DNA and resulting in DNA breaks,
inhibition of DNA replication and apoptosis in HER3-expressing tumor cells. HER3,
a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine
kinases, is frequently overexpressed in tumors.;
Molecule name : YL-202; YL 202;
NCI Metathesaurus CUI : CL1906222;
Origin ID : C199281;
concept_is_in_subset
- has_target
